AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2570286 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 69 578 (a competitive inhibitor of endopeptidase 24.11)
Number of subjects: 0
Study 326494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin cream
Number of subjects: 31
Study 326494 — intervention group
Group type: COMPARATOR
Intervention: Nystatin/triamcinolone acetonide combination cream
Number of subjects: 31
Study 31362145 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry Outcome Journal (WOJ)
Number of subjects: 51
Study 31362145 — intervention group
Group type: COMPARATOR
Intervention: Thought Log (TL)
Number of subjects: 51
Study 28985238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) after DOMS
Number of subjects: 20
Study 28985238 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Isometric Voluntary Force (MIVF)
Number of subjects: 20
Study 28985238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) after 72 hours
Number of subjects: 20
Study 28985238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Detection Threshold (MDT) and Mechanical Pain Threshold (MPT)
Number of subjects: 20
Study 26044879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-brief intervention (UBI) delivered in three GP appointments over five weeks.
Number of subjects: 0
Study 26044879 — intervention group
Group type: COMPARATOR
Intervention: Practice as usual (control group).
Number of subjects: 0
Study 23474890 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine/Paracetamol 20/400 mg
Number of subjects: 16
Study 23474890 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine/Paracetamol 40/800 mg
Number of subjects: 16
Study 23474890 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine/Paracetamol 60/1200 mg
Number of subjects: 16
Study 23474890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21465774 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetolaserotherapy and n‐3 polyunsaturated fatty acids
Number of subjects: 0
Study 19128957 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative sentinel node biopsy without axillary dissection
Number of subjects: 3548
Study 19128957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 3548
Study 17559697 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-OO
Number of subjects: 21
Study 17559697 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-SO
Number of subjects: 21
Study 17559697 — intervention group
Group type: COMPARATOR
Intervention: OO
Number of subjects: 21
Study 15067655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 20 mL 0.5% (100 mg)
Number of subjects: 60
Study 15067655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL normal saline)
Number of subjects: 60
Study 11535549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 29
Study 11535549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9647497 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-based vegetarian low-protein diet (VPD)
Number of subjects: 15
Study 9647497 — intervention group
Group type: COMPARATOR
Intervention: Animal-based low-protein diet (APD)
Number of subjects: 15
Study 9647497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 15
Study 8291821 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session, nurse-delivered behavior modification program using a videotape and face-to-face counseling
Number of subjects: 93
Study 8291821 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study 3290233 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial agent
Number of subjects: 251
Study 3290233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 31948604 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel therapy
Number of subjects: 110
Study 31948604 — intervention group
Group type: COMPARATOR
Intervention: Classic wound dressing (Control)
Number of subjects: 110
Study 28503722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation (OS)
Number of subjects: 82
Study 28503722 — intervention group
Group type: COMPARATOR
Intervention: Control (no ovarian stimulation)
Number of subjects: 82
Study 26612286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with midazolam (DM)
Number of subjects: 50
Study 26612286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil with midazolam (SM)
Number of subjects: 50
Study 23574758 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Assessment of Chronic Illness Care (PACIC) instrument
Number of subjects: 945
Study 21440263 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial sealant (Kimberly‐Clark InteguSeal) applied to one leg
Number of subjects: 47
Study 21440263 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation of the other leg
Number of subjects: 47
Study 20038402 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-interventional antibiotic treatment with cefuroxime, 20 mg/kg three times per day for 24 hours
Number of subjects: 40
Study 20038402 — intervention group
Group type: COMPARATOR
Intervention: Prolonged antibiotic treatment with cefuroxime, 20 mg/kg three times per day for 7 days
Number of subjects: 40
Study 16550663 — intervention group
Group type: EXPERIMENTAL
Intervention: Two hours of warming immediately after surgery
Number of subjects: 45
Study 16550663 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed groups (two hours and seven days of warming)
Number of subjects: 45
Study 16550663 — intervention group
Group type: COMPARATOR
Intervention: No warming (control group)
Number of subjects: 45
Study 16550663 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven days of warming
Number of subjects: 45
Study 15329902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin at 50 mg/m2 every 4 weeks for 6 cycles (Group B)
Number of subjects: 48
Study 15329902 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin at 25 mg/m2 every 2 weeks for 12 cycles (Group A)
Number of subjects: 48
Study 15329902 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (50 mg/m2 every 4 weeks for 6 cycles)
Number of subjects: 48
Study 15329902 — intervention group
Group type: COMPARATOR
Intervention: Group A (25 mg/m2 every 2 weeks for 12 cycles)
Number of subjects: 48
Study 11061509 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (ARG; 0.5 g/kg, iv, from 0-30 min)
Number of subjects: 6
Study 11061509 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human IGF-I (rhIGF-I; 20 microg/kg, sc, at -180 min)
Number of subjects: 6
Study 11061509 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus ARG
Number of subjects: 6
Study 9570358 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid carcinoma
Number of subjects: 0
Study 9570358 — intervention group
Group type: COMPARATOR
Intervention: Hepatocellular carcinoma
Number of subjects: 0
Study 9570358 — intervention group
Group type: COMPARATOR
Intervention: Transitional cell carcinoma
Number of subjects: 0
Study 9570358 — intervention group
Group type: COMPARATOR
Intervention: Gastric adenocarcinoma
Number of subjects: 0
Study 8117630 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural morphine
Number of subjects: 27
Study 8117630 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural morphine
Number of subjects: 27
Study 8117630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Thoracic and Lumbar)
Number of subjects: 27
Study 2868337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK) in addition to usual treatment
Number of subjects: 11712
Study 2868337 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual treatment only)
Number of subjects: 11712
Study 2868337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 11712
Study 29681640 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical low‐coherence reflectometry (OLCR)
Number of subjects: 30
Study 29681640 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic pachymetry (US)
Number of subjects: 30
Study 29681640 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OLCR and US
Number of subjects: 30
Study 27492105 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 36
Study 27492105 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral untreated eyes)
Number of subjects: 36
Study 24999127 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT) using blue rhino technique
Number of subjects: 80
Study 24999127 — intervention group
Group type: COMPARATOR
Intervention: Surgical tracheostomy (ST) using Charles G Durbin technique
Number of subjects: 80
Study 22874424 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate beverage (3.4 g glucose + 3.1 g fructose per deciliter)
Number of subjects: 7
Study 22874424 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (0.0 g glucose + 0.0 g fructose per deciliter)
Number of subjects: 7
Study 22874424 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate beverage (1.7 g glucose + 1.6 g fructose per deciliter)
Number of subjects: 7
Study 20336817 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational internet web pages (addresses of three relevant anaesthesia and health-related websites)
Number of subjects: 0
Study 20336817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to informational web pages)
Number of subjects: 0
Study 18249327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 1059
Study 15879435 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled corticosteroid)
Number of subjects: 436
Study 15879435 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (beta-agonist) with glucocorticoid
Number of subjects: 436
Study 15879435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 14673758 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 microg administered subcutaneously 3 times/week for 16 weeks
Number of subjects: 116
Study 14673758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 14673758 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 116
Study 10410058 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 20
Study 10410058 — intervention group
Group type: COMPARATOR
Intervention: Music appreciation sessions (Control)
Number of subjects: 20
Study 8883267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin (5000 U bolus followed by 1000 U/h infusion)
Number of subjects: 28
Study 8883267 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous heparin (12,500 U every 12 h, started 4 h after streptokinase)
Number of subjects: 28
Study 8883267 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with activated partial thromboplastin time greater than two times the control
Number of subjects: 28
Study 1517726 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention (10-15 minute discussion and handout)
Number of subjects: 238
Study 1517726 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special intervention)
Number of subjects: 238
Study 6091079 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid preparations
Number of subjects: 0
Study 29786954 — intervention group
Group type: COMPARATOR
Intervention: Urinary metabolites analysis using NMR spectroscopy at day 10
Number of subjects: 75
Study 29786954 — intervention group
Group type: COMPARATOR
Intervention: Urine lactate and pyroglutamate levels
Number of subjects: 75
Study 29786954 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression analysis of metabolite ratios
Number of subjects: 75
Study 29786954 — intervention group
Group type: COMPARATOR
Intervention: Metabolite ratios (lactate/fumarate and BCAAs/pyroglutamate)
Number of subjects: 75
Study 30183260 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel formulation of dapivirine
Number of subjects: 0
Study 30183260 — intervention group
Group type: COMPARATOR
Intervention: Film-based formulation of dapivirine
Number of subjects: 0
Study 27111184 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/sexually transmitted infection (STI) risk‐reduction intervention
Number of subjects: 786
Study 25205868 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTF (Ciliary neurotrophic factor) delivered via intraocular microcapsules (20 ng/d)
Number of subjects: 5
Study 25205868 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTF (Ciliary neurotrophic factor)
Number of subjects: 5
Study 25205868 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated fellow eyes)
Number of subjects: 5
Study 22842237 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week preconditioning programme (PRECON) with walking and hopping exercises (N=211)
Number of subjects: 432
Study 22842237 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=221)
Number of subjects: 432
Study 22842237 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PRECON and Control
Number of subjects: 432
Study 20416132 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg per day for 6 weeks
Number of subjects: 20
Study 20416132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18092452 — intervention group
Group type: EXPERIMENTAL
Intervention: LANAP treatment with Nd:YAG laser
Number of subjects: 12
Study 18092452 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (scaling and root planing without laser)
Number of subjects: 12
Study 16178945 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 570
Study 16178945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 570
Study 16178945 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 570
Study 16178945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 12632439 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (triamcinolone hexacetonide 40 mg) + supervised physiotherapy
Number of subjects: 93
Study 12632439 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection alone
Number of subjects: 93
Study 12632439 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline injection + supervised physiotherapy
Number of subjects: 93
Study 12632439 — intervention group
Group type: COMPARATOR
Intervention: Saline injection alone (placebo group)
Number of subjects: 93
Study 10503056 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory icons (car horn and skidding tyres)
Number of subjects: 0
Study 10503056 — intervention group
Group type: COMPARATOR
Intervention: Conventional warnings (simple tone and voice saying 'ahead')
Number of subjects: 0
Study 8719534 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic cream (EMLA)
Number of subjects: 16
Study 8719534 — intervention group
Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 16
Study 1827575 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 1,200 mg/day (Group A: 28 patients)
Number of subjects: 48
Study 1827575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA) 100 mg/day in combination with MPA (Group B: 20 patients)
Number of subjects: 48
Study 1827575 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 1,200 mg/day (Group A)
Number of subjects: 48
Study 1827575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA) 100 mg/day in combination with MPA (Group B)
Number of subjects: 48
Study 7387963 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon arc photocoagulation treatment
Number of subjects: 99
Study 7387963 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 99
Study 30595080 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL (neutrophil gelatinase‐associated lipocalin)
Number of subjects: 1131
Study 28096223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with pioglitazone plus weekly exenatide
Number of subjects: 231
Study 28096223 — intervention group
Group type: COMPARATOR
Intervention: Basal plus prandial insulin therapy
Number of subjects: 231
Study 27352329 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete video-assisted thoracoscopic surgery (c-VATS) lobectomy
Number of subjects: 100
Study 27352329 — intervention group
Group type: COMPARATOR
Intervention: Conventional lobectomy via thoracotomy
Number of subjects: 100
Study 23781953 — intervention group
Group type: EXPERIMENTAL
Intervention: NLC group (2-mm needle-shape instruments)
Number of subjects: 60
Study 23781953 — intervention group
Group type: COMPARATOR
Intervention: SILC group (single-incision laparoscopic cholecystectomy)
Number of subjects: 60
Study 23781953 — intervention group
Group type: EXPERIMENTAL
Intervention: NLC group
Number of subjects: 60
Study 23781953 — intervention group
Group type: COMPARATOR
Intervention: SILC group
Number of subjects: 60
Study 21991732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 100
Study 21991732 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg)
Number of subjects: 100
Study 21991732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) + Bupivacaine (5 mg/ml)
Number of subjects: 100
Study 21991732 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg) + Bupivacaine (5 mg/ml)
Number of subjects: 100
Study 19438906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant monotherapy (PM) - 10 mg once daily initially, adjusted in 5-mg increments every 8 weeks based on IGF‐I levels
Number of subjects: 27
Study 19438906 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy of pegvisomant and long-acting octreotide (P-LAR) - LAR dosing remained fixed
Number of subjects: 27
Study 17276147 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (OD) tobramycin
Number of subjects: 0
Study 17276147 — intervention group
Group type: COMPARATOR
Intervention: Three times daily (TD) tobramycin
Number of subjects: 0
Study 14665792 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 129
Study 14665792 — intervention group
Group type: COMPARATOR
Intervention: Relaxation tape recordings
Number of subjects: 129
Study 12742501 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin-eluting coronary artery stents
Number of subjects: 0
Study 9476845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (QEA, PSB, BAL)
Number of subjects: 51
Study 9476845 — intervention group
Group type: COMPARATOR
Intervention: Group B (QEA only)
Number of subjects: 51
Study 9476845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 51
Study 9476845 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 51
Study 8751024 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet-injection of recombinant human growth hormone (rhGH)
Number of subjects: 12
Study 8751024 — intervention group
Group type: COMPARATOR
Intervention: Needle-injection of recombinant human growth hormone (rhGH)
Number of subjects: 12
Study 8751024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (jet-injection and needle-injection)
Number of subjects: 12
Study 2208022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Number of subjects: 256
Study 2208022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of chemotherapy
Number of subjects: 256
Study 758386 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy at extubation
Number of subjects: 65
Study 758386 — intervention group
Group type: COMPARATOR
Intervention: No physiotherapy
Number of subjects: 65
Study 758386 — intervention group
Group type: COMPARATOR
Intervention: Pre-physio period
Number of subjects: 65
Study 31654397 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (N2O)
Number of subjects: 0
Study 31654397 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28272716 — intervention group
Group type: EXPERIMENTAL
Intervention: NBCA medical adhesive for patch fixation
Number of subjects: 160
Study 28272716 — intervention group
Group type: COMPARATOR
Intervention: Without patch fixation (control group)
Number of subjects: 160
Study 25950140 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (INT)
Number of subjects: 118
Study 25950140 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 118
Study 24255071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Number of subjects: 201
Study 24255071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 21353720 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administered concurrently with radiotherapy (RT)
Number of subjects: 38
Study 21353720 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (66 Gy in 33 fractions or 45 Gy in 30 fractions) with cisplatin and etoposide
Number of subjects: 38
Study 19210693 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/RTV 800/100 mg qd
Number of subjects: 49
Study 19210693 — intervention group
Group type: COMPARATOR
Intervention: atazanavir/RTV 300/100 mg qd
Number of subjects: 49
Study 17944734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with stepwise reduction of CNI
Number of subjects: 75
Study 17944734 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintenance CNI dose)
Number of subjects: 75
Study 17944734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 75
Study 15083442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (behavioral techniques, social support, education to promote exercise)
Number of subjects: 75
Study 15083442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 11422884 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Number of subjects: 7